EPCAM and cancer: In the same year, Tsai et al. verified the single EpCAM-dependent CellMax platform as an early cancer detection method due to its ability to relate the captured epithelial CTCs count to different CRC stages (adenomas, stage I, II, III, IV) with a positive detection rate up to 94.5% (307/325 patients) [30].